1Q 20

Financial Results

BAUSCH Health

Forward-Looking Statements

This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements regarding Bausch Health's future prospects and performance (including the Company's 2020 full-year guidance and targeted three-year CAGR[1] of revenue growth and Adjusted EBITDA (non-GAAP) growth), expectations for cash generated from operations and the anticipated uses of same, expectations regarding gross margin, the anticipated impact of the COVID-19 pandemic on the Company and its financial condition, results of operation, revenues, segments, liquidity, products and product pipeline, operations, facilities, supply chain and employees, planned efforts to address the COVID-19 pandemic (including planned clinical trials, planned donations and continued commitment to patient access), expected durability of certain of our products and brands, the anticipated submission, approval and launch dates for certain of our pipeline products and R&D programs, the anticipated timing of commencement of studies or other development work of our pipeline products and R&D programs, the anticipated timing of the loss of exclusivity of certain of our products and the expected impact of such loss of exclusivity on our financial condition, expected growth in R&D and the amount of such growth, management's commitments and expected targets and our ability to achieve the action plan and expected targets in the periods anticipated, the Company's mission (and the elements and timing thereof) and the Company's plans and expectations for 2020 and beyond. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects,“ "predicts," "goals," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," "commit," "forecast," "tracking," or "continue" and variations or similar expressions, and phrases or statements that certain actions, events or results may, could, should or will be achieved, received or taken or will occur or result, and similar such expressions also identify forward-looking information. These forward-looking statements, including the Company's 2020 full-year guidance and targeted three-year CAGR of revenue growth and Adjusted EBITDA (non-GAAP) growth, are based upon the current expectations and beliefs of management and are provided for the purpose of providing additional information about such expectations and beliefs and readers are cautioned that these statements may not be appropriate for other purposes. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results and events to differ materially from those described in these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Company's most recent annual and quarterly reports and detailed from time to time in the Company's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which risks and uncertainties are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on the Company, including but not limited to its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition and costs (which may increase) and revenue and margins (both of which may decrease). In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including, without limitation, assumptions regarding our 2020 full-year guidance with respect to expectations regarding base performance and management's belief regarding the impact of the COVID-19 pandemic and associated responses on such base performance and the operations and financial results of the Company generally, expected currency impact, the expected timing and impact of loss of exclusivity for certain of our products, adjusted SG&A expense (non-GAAP) and the Company's ability to continue to manage such expense in the manner anticipated, the anticipated timing and extent of the Company's R&D expense, expectations regarding gross margin; assumptions respecting our targeted three-year CAGR of revenue growth and Adjusted EBITDA (non-GAAP) growth including, without limitation, management's belief regarding the impact of the COVID-19 pandemic and associated responses on the operations and financial results of the Company, constant currency and from mid-point of Feb. 2019 guidance (adjusted for current exchange rates); and assumptions that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. Additional information regarding certain of these material factors and assumptions may also be found in the Company's filings described above. Management has also made certain assumptions in assessing the anticipated impacts of the COVID-19 pandemic on the Company and its results of operations and financial conditions (see Slide 17 for further details). If any of these assumptions regarding the impacts of the COVID-19 pandemic are incorrect, our actual results could differ materially from those described in these forward-looking statements. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable in the circumstances, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes, unless required by law.

The guidance in this presentation is only effective as of the date given, May 7, 2020, and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance.

Distribution or reference of this deck following May 7, 2020 does not constitute the Company re-affirming guidance.

BAUSCH Health

1. Compound Annual Growth Rate.

Non-GAAP Information

To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures including (i) Adjusted EBITDA, (ii) Adjusted EBITA, (iii) EBITA, (iv) EBITA Margin, (v) Adjusted Gross Profit/Adjusted Gross Margin (vi) Adjusted Selling, A&P, (vii) Adjusted G&A, (viii) Adjusted SG&A, (ix) Total Adjusted Operating Expense, (x) Adjusted Net Income, (xi) Adjusted Tax Rate, (xii) Organic Revenue, Organic Growth, Organic Change and Organic Revenue Decline and (xiii) Constant Currency. Management uses some of these non-GAAP measures as key metrics in the evaluation of Company performance and the consolidated financial results and, in part, in the determination of cash bonuses for its executive officers. The Company believes these non-GAAP measures are useful to investors in their assessment of our operating performance and the valuation of the Company. In addition, these non-GAAP measures address questions the Company routinely receives from analysts and investors and, in order to assure that all investors have access to similar data, the Company has determined that it is appropriate to make this data available to all investors.

However, these measures are not prepared in accordance with GAAP nor do they have any standardized meaning under GAAP. In addition, other companies may use similarly titled non-GAAP financial measures that are calculated differently from the way we calculate such measures. Accordingly, our non-GAAP financial measures may not be comparable to such similarly titled non-GAAP measures. We caution investors not to place undue reliance on such non-GAAP measures, but instead to consider them with the most directly comparable GAAP measures. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

The reconciliations of these historic non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP are shown in the appendix hereto. However, for guidance and expected CAGR[1] purposes, the Company does not provide reconciliations of projected Adjusted EBITDA (non-GAAP) to projected GAAP net income (loss), due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations. In periods where significant acquisitions or divestitures are not expected, the Company believes it might have a basis for forecasting the GAAP equivalent for certain costs, such as amortization, that would otherwise be treated as a non-GAAP adjustment to calculate projected GAAP net income (loss). However, because other deductions (e.g., restructuring, gain or loss on extinguishment of debt and litigation and other matters) used to calculate projected net income (loss) may vary significantly based on actual events, the Company is not able to forecast on a GAAP basis with reasonable certainty all deductions needed in order to provide a GAAP calculation of projected net income (loss) at this time. The amounts of these deductions may be material and, therefore, could result in GAAP net income (loss) being materially different from (including materially less than) projected Adjusted EBITDA (non-GAAP).

1. *Compound Annual Growth Rate.*

Today's Topics

COVID-19 Perspective & 1Q20 Highlights

Response to COVID-19: Ensuring Business Continuity

Employees

- Health and safety of our employees is paramount. Senior management continues to assess the situation and implement actions to protect our colleagues.

Liquidity

- We are in a strong position from a liquidity standpoint
- No mandatory amortization payments or debt maturities until 2022
- $1.225B revolving credit facility undrawn

Supply Chain

- Our supply chain and manufacturing facilities are operational
- To date, we have not seen any material COVID-19 related supply disruptions
- Availability of API and Intermediates have not had, and at this time we do not expect will have, a material impact on our supply chain. We have multiple sources of API and Intermediates for many of our products.
- With respect to our largest product, XIFAXAN®, we have over five months' supply of XIFAXAN on hand and enough API to manufacture over five months' supply of XIFAXAN finished goods.

Commercial Capabilities

- Supporting health care professionals virtually to ensure continued support in countries where in-person interactions have been suspended

R&D

- Working with health authorities and investigators to protect our trial participants, personnel and our clinical trial sites
- Continuing our regular interactions with our regulatory authorities

Advancing Science to Help Find Solutions for COVID-19

- Initiated clinical trial programs in Canada evaluating investigational use of antiviral nebulization VIRAZOLE® (Ribavirin for Inhalation Solution, USP) in combination with standard of care therapy to treat hospitalized adult patients with respiratory distress due to COVID-19

- Working toward investigative trials in U.S. to evaluate XIFAXAN® (rifaximin) to potentially address symptoms of gastrointestinal distress and pulmonary compromise associated with COVID-19 infection
  - If successful in resolving symptoms or reducing duration of COVID-19, the company will donate XIFAXAN to various hospitals

- Ramped up manufacturing of chloroquine and azithromycin and donated these products to local hospitals (Spain and Italy)

Providing Needed Medical Supplies

- Making available for donation nebulized VIRAZOLE® (Ribavirin for Inhalation Solution, USP) for compassionate use in hospitals (Italy)

- Donated ARTELAC® Splash™ eye drops to local hospitals to reduce eye irritation and the risk of eye infection by alleviating possible symptoms of dry eye among health care providers (Spain)

- Donated Biotrue® ONEday daily disposable contact lenses to health care providers to alleviate reported fogging of eyeglasses while wearing protective gear, such as goggles, face masks and containment suits (Wuhan, China)

- Conversion of production lines (Jinan, China and Laval, Quebec) to produce hand sanitizer for intended donation to health care providers, first responders and volunteers

Continued Commitment to Patient Access

- Bausch Health Patient Assistance Program (PAP) continues to ensure that eligible U.S. patients in need who lack health insurance coverage for certain Bausch Health medicines are able to access their prescription medicines.

- During this time when many health care offices are not operating on regular schedules, the PAP has increased its efforts to work with patients and physicians' offices to ensure patients have uninterrupted access to their medicines.

Impact from COVID-19 on 1Q20 Results

- During 1Q20, COVID-19 impacted revenue by ~$35M, which negatively impacted 1Q20 revenue by ~2%
  - + "Pantry loading" positively impacted revenue by ~$30M, including in Global Consumer and U.S. Vision Care
  - – Offset by negative COVID-19 impact to revenue of ~$65M
- Postponement in elective procedures were directed by public health authorities, affecting Global Solta and Surgical business units, as well as Ophtho Rx with pre/post-operative prescriptions declining
- Declines in International Vision Care as a result of retail store closures as well as reduced contact lens wear due to decreased social interaction
- Ortho Dermatologics and Dentistry business units saw prescription declines in March due to office closures in U.S.

Bausch Health Update – 1Q20

BAUSCH Health | Organic Revenue Growth[1,2]: 0% | Reported Revenue Growth: 0%

Key Drivers in 1Q20

- Bausch + Lomb/International delivered its 14th consecutive quarter of overall organic revenue growth[1,2] despite headwinds from COVID-19
  - Global Consumer: Strong growth in eye vitamin franchise (particularly PreserVision®), LUMIFY® growth, and "pantry loading" in response to COVID-19
  - International Rx: Growth driven by sales in Canada and Eastern Europe
  - Global Vision Care: Negatively impacted from COVID-19 especially in Asia Pacific, partially offset by U.S. Vision Care which saw a 24% increase in organic revenue[1,2] vs. 1Q19, driven by the performance of Biotrue® ONEday and ULTRA®
- Salix reported mid-single digit organic growth vs. 1Q19, despite ~$40M LOE headwind, primarily APRISO®
  - XIFAXAN® saw ~6% TRx growth vs. 1Q19 while extended units saw ~6.5% growth vs. 1Q19[3]
  - TRULANCE® generated $19M in revenue for 1Q20 with TRx growth of ~52% vs. 1Q19[3]
  - RELISTOR® revenue increased by 19% vs. 1Q19, as a result of growth in the oral formulation

Additional Highlights

- Repaid ~$220M of debt in 1Q20 using cash generated from operations[5]
- No mandatory amortization payments or debt maturities until 2022

Notable Key Developments

Resolved XIFAXAN® IP litigation with Sandoz

- Preserved market exclusivity until 2028[6]

Market Access

- VYZULTA®: Increased Medicare Part D access to ~45% up from ~30%[4]
- LOTEMAX® SM: Increased Medicare Part D access to ~55% up from ~40%[4]

R&D

- Amiselimod S1P Modulator: Completed the thorough QT study which evaluated the cardiac safety profile; topline results were positive and expect to initiate Phase 2 study in 2H20
- Rifaximin (OHE): Favorable topline results

2020 New Launches

- ARAZLO® launch on track for 1H20
- SiHy Daily launch in U.S. on track for 2H20
- Probiotic launch on track for 2H20

1. See Slide 2 and Appendix for further non-GAAP information.
2. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.
3. IQVIA NPA monthly.
4. Increased access starting on July 1, 2020.
5. Subsequent to 3/31/2020, the Company repaid a further $8M of unsecured notes scheduled to mature in 2023.
6. Sandoz will be able to begin marketing the medicine earlier if another generic rifaximin product is granted approval and starts selling or distributing such generic rifaximin product before Jan 1, 2028.

1Q20 Financial Results

1Q20 Revenue Results

	Three Months Ended		Favorable (Unfavorable)	
	3.31.20	*3.31.19*	*Reported*	*Organic Change[1,2]*
Bausch + Lomb/International	**$1,114M**	**$1,118M**	**0%**	**2%**
Global Vision Care Revenue	$193M	$203M	(5%)	(3%)
Global Surgical Revenue	$153M	$167M	(8%)	(6%)
Global Consumer Revenue	$353M	$324M	9%	12%
Global Ophtho Rx Revenue	$132M	$161M	(18%)	(16%)
International Rx Revenue	$283M	$263M	8%	9%
Salix	**$477M**	**$445M**	**7%**	**4%**
Ortho Dermatologics	**$133M**	**$138M**	**(4%)**	**(3%)**
Ortho Dermatologics	$82M	$100M	(18%)	(18%)
Global Solta	$51M	$38M	34%	37%
Diversified Products	**$288M**	**$315M**	**(9%)**	**(9%)**
Neuro & Other Revenue	$162M	$186M	(13%)	(13%)
Generics Revenue	$105M	$104M	1%	1%
Dentistry Revenue	$21M	$25M	(16%)	(16%)
Total Company	**$2,012M**	**$2,016M**	**0%**	**0%**

BAUSCH Health

1. *See Slide 2 and Appendix for further non-GAAP information.*
2. *Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.*

1Q 20 Financial Results

	Three Months Ended		Favorable (Unfavorable)		
	3.31.20	*3.31.19*	*Reported*	*Constant Currency*[1,2]	*Organic Change*[1,3]
Revenues	$2,012M	$2,016M	0%	1%	0%
GAAP Net Loss	($152M)	($52M)			
Adj. Net Income (non-GAAP)[1] ***Diluted Shares Outstanding***[5]	$316M ***358.6M***	$358M ***356.2M***	(12%)	(7%)	
GAAP EPS	($0.43)	($0.15)			
GAAP CF from Operations	$261M	$413M	(37%)		
Adj. Gross Profit (non-GAAP)[4,6] (excluding amortization and impairments of intangible assets)	$1,493M	$1,480M	1%	2%	
Adj. Gross Margin (non-GAAP)[6]	74.2%	73.4%	80 bps		
Selling, A&P	$469M	$462M	(2%)	(3%)	
Adj. G&A (non-GAAP)[1]	$148M	$113M	(31%)	(32%)	
R&D	$122M	$117M	(4%)	(5%)	
Total Adj. Operating Expense (non-GAAP)[1]	$739M	$692M	(7%)	(8%)	
Adj. EBITA (non-GAAP)[1]	$754M	$788M	(4%)	(3%)	
Adj. EBITDA (non-GAAP)[1]	$813M	$851M	(4%)	(2%)	

1. *See Slide 2 and Appendix for further non-GAAP information.*
2. *See Appendix for further information on the use and calculation of constant currency.*
3. *Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.*
4. *See Appendix for details on amortization and impairments of intangible assets.*
5. *This figure includes the dilutive impact of options and restricted stock units of approximately 5,207,000 and 4,920,000 common shares for the three months ended March 31, 2020 and 2019, respectively, which are excluded when calculating GAAP diluted loss per share because the effect of including the impact in those calculations would have been anti-dilutive.*
6. *2020 numbers are on an as reported basis, no adjustments reflected in 2020.*

1Q 20

Cash Flow Summary

	Three Months Ended 3.31.20	*Three Months Ended 3.31.19*
Net loss[1]	($152M)	($48M)
Net cash provided by operating activities	$261M	$413M
Net cash used in investing activities	($40M)	($203M)
Net cash used in financing activities[3]	($1,521M)[2]	($150M)
Net (decrease) increase in cash, cash equivalents and restricted cash[3]	($1,321M)[2]	$61M
Cash, cash equivalents and restricted cash at end of period	$1,923M[4]	$784M

$261M of cash generated from operations during 1Q20, which was negatively impacted by (as compared to 1Q19):

- ~$85M working capital[5]
- ~$40M due to timing of interest payments
- ~$25M due to license agreement

BAUSCH Health

1. Net loss before net income attributable to non-controlling interests.
2. Includes $1,240 million redemption of 5.875% May 2023 Notes using proceeds from the December 2019 bond issuance.
3. Includes net impact of activity under our revolving credit facility (if any).
4. Includes remaining net proceeds from Dec. 2019 $2,500M bond issuance intended to be used to finance the $1,210M pending settlement of the U.S. Securities litigation due in 2020.
5. Refers to inventory, receivables and payables.

1Q 20 Balance Sheet Summary

	As of 3.31.20	As of 12.31.19	As of 9.30.19	As of 6.30.19	As of 3.31.19
Cash, cash equivalents and restricted cash	$1,923M[1]	$3,244M[2]	$827M	$880M	$784M
Revolving Credit Drawn	$0M	$0M	$0M	$150M	$0M
Senior Secured Debt[3]	$10,541M	$10,644M	$10,744M	$11,197M	$11,147M
Senior Unsecured Debt[3]	$14,160M	$15,544M	$13,097M	$13,172M	$13,327M
Total Debt[3]	$24,701M	$26,188M	$23,841M	$24,369M	$24,474M
Net Debt[4]	$23,789M[5]	$22,945M[6]	$23,016M	$23,491M	$23,692M
TTM[7] Adj. EBITDA (non-GAAP)[8]	$3,533M	$3,571M	$3,531M	$3,505M	$3,493M

Repaid ~$220M of debt; no mandatory amortization payments or debt maturities until 2022[9]

1. *Includes remaining net proceeds from Dec. 2019 bond issuance intended to be used to finance the $1,210M pending settlement of the U.S. Securities litigation due in 2020.*
2. *Includes remaining net proceeds from Dec. 2019 bond issuance intended to be used to: (i) finance the $1,210M pending settlement of the U.S. Securities litigation due in 2020 and (ii) replace $1,240M of debt due May 2023 on Jan. 16, 2020.*
3. *Debt balances shown at principal value. Senior secured debt figure is inclusive of revolving credit drawn (if any).*
4. *Total Debt net of unrestricted cash and cash equivalents.*
5. *Restricted cash and cash equivalents as of 3/31/20 includes $1,010M intended to be used to finance the $1,210M pending settlement of the U.S. Securities litigation in 2020. This $1,010M does not reduce net debt as of 3/31/20. Net Debt as of 3/31/20 is reduced by the remaining $200M of the $1,210M which is not in restricted cash.*
6. *Net Debt as of 12/31/19 is reduced by the $1,210M, no part of which is in restricted cash as of 12/31/19, intended to be used to finance the pending settlement of the U.S. Securities litigation due in 2020.*
7. *Trailing Twelve Months.*
8. *See Slide 2 and Appendix for further non-GAAP information.*
9. *Subsequent to 3/31/2020, the Company repaid a further $8M of unsecured notes scheduled to mature in 2023.*

BAUSCH Health

No Debt Maturities Until 2022

Long-Term Debt Maturity Profile as of May 7, 2020[1]

	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	Total
Debt Maturities	-	-	$1,250M	$2,140M	$2,000M	$10,518M	$1,500M	$2,250M	$2,012M	$750M	$1,250M	$23,670M
Mandatory Amortization	-	-	$303M	$303M	$303M	$114M	-	-	-	-	-	$1,023M
Total	-	-	$1,553M	$2,443M	$2,303M	$10,632M	$1,500M	$2,250M	$2,012M	$750M	$1,250M	$24,693M

- No mandatory amortization payments or debt maturities until 2022, all of which are of a secured nature
- As of March 31, 2020, **~80% of debt is fixed rate debt**; remaining ~20% is secured floating
- Redeemed $1,240M aggregate principal value of 5.875% May 2023 Notes in January 2020 using proceeds from the December 2019 bond issuance.
- YTD as of May 7, 2020, repaid ~$230M of debt using cash generated from operations

BAUSCH Health

1. *Debt values are shown at principal value.*

FY 2020 Guidance

COVID-19 Impact Expected Across BHC Segments[1]

Least Impacted → **Most Impacted**

~67% of Total Revenue

~44% of Total Revenue

Global Consumer
Neuro & Other
Generics
International Rx

~23% of Total Revenue

Salix

XIFAXAN® HE
TRULANCE® CIC

XIFAXAN® IBS-D
TRULANCE® IBS-C

~33% of Total Revenue

~20% of Total Revenue

Global Vision Care
Global Solta
Global Ophtho Rx

~13% of Total Revenue

Ortho Dermatologics
Dentistry
Global Surgical

BAUSCH Health

1. Total Revenue Percentages are for the Twelve Months Ended December 31, 2019.

2020 Key Guidance Assumptions

Broad Assumptions

- A potential resurgence of the virus in 2H20 would not see severe social restrictions put in place by local authorities (e.g., shelter at home, closure of non-essential businesses, deferral of elective medical procedures, etc.).
- Global economies will recover as COVID-19 runs its course and social restrictions are eased.

Business Impact and Recovery Assumptions

- Largest impact to our businesses seen in 2Q due to stay-at-home orders, office closures, retail closures and deferral of surgical procedures
- Recovery expected to begin towards the latter part of 2Q and continue into 3Q and 4Q
- We expect our businesses to return to pre-COVID-19 levels at different rates, starting as early as 3Q of 2020 but spread into 4Q and beyond. For example, we do not believe the backlog of eye surgeries will be resolved in 2020.
- Some of our business units (Global Surgical, Ortho Dermatologics and Dentistry) are expected to lag in the recovery, some possibly beyond 2021.
- Assumes no major interruptions in our supply chain and distribution channels

Full-Year 2020 Revenue and Adjusted EBITDA (non-GAAP)[1] Guidance[3,4]

	Prior Guidance (February 2020)	Current Guidance (May 2020)
Total Revenues	**$8.65B - $8.85B**	**$7.80B - $8.20B**
Adjusted EBITDA (non-GAAP)[1]	**$3.50B - $3.65B**	**$3.15B - $3.35B**

Key Assumptions	Prior Guidance (February 2020)	Current Guidance (May 2020)
Adj. SG&A Expense (non-GAAP)[1]	**~$2.6B**	**~$2.4B**
R&D Expense	**~$500M**	**~$475M**
Interest Expense[2]	**~$1.55B**	**~$1.55B**
Adj. Tax Rate (non-GAAP)[1]	**~8%**	**~8%**
Avg. Fully Diluted Share Count	**362M**	**362M**
Additional Non-Cash Assumptions		
Depreciation	**~$185M**	**~$185M**
Stock-Based Compensation	**~$115M**	**~$110M**
Additional Cash Item Assumptions		
Capital Expenditures	**~$300M**	**~$275M**
Contingent Consideration / Milestones / License Agreements	**~$100M**	**~$75M**
Restructuring and Other	**~$75M**	**~$75M**

Cash generated from operations for 2020 is expected to be ~$1B[5]

Gross margin for 2020 is expected to be ~73%

Revised 3-year CAGRs[6]
(constant currency and from the mid-point of 2019 guidance[7])

- **Expect revenue to grow at a 3%-5% CAGR[6]**
- **Expect adj. EBITDA (non-GAAP)[1] to grow at a 4%-7% CAGR[6]**

1. See Slide 2 and Appendix for further non-GAAP information.
2. Interest expense includes amortization and write-down of deferred financing costs of ~$50M.
3. The guidance in this presentation is only effective as of the date given, May 7, 2020, and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance. Distribution or reference of this deck following May 7, 2020 does not constitute the Company re-affirming guidance.
4. See Slide 1 for further information on forward-looking statements.
5. Excludes legacy legal settlements.
6. Compound Annual Growth Rate.
7. Based on Guidance issued in Feb. 2019.

BAUSCH Health

Revised Long-Term CAGRs[1]

Original 3-year CAGR[1] Assumptions (2019-2022)

Constant currency and from the original mid-point of 2019 guidance[2]

Revenue

Midpoint 2019 Guidance	FX May 2020 vs. Feb. 2019	At May 2020 FX Rates
$8,400M	($170M)	$8,230M

Adj. EBITDA

Midpoint 2019 Guidance	FX May 2020 vs. Feb. 2019	At May 2020 FX Rates
$3,425M	($70M)	$3,355M

Revenue CAGR[1] from 2019 Guidance to 2022

2022 Projection Based on Prior CAGR of 4-6%

$9,260M to $9,800M

2022 Projection Based on Current CAGR of 3-5%

★ $8,995M to $9,525M

Change at mid-point (~$270M)

Adj. EBITDA CAGR[1] from 2019 Guidance to 2022

2022 Projection Based on Prior CAGR of 5-8%

$3,885M to $4,225M

2022 Projection Based on Current CAGR of 4-7%

★ $3,775M to $4,110M

Change at mid-point (~$115M)

BAUSCH Health

1. Compound Annual Growth Rate.
2. Based on Guidance issued in Feb. 2019.

Full-Year 2020 Revenue and Adjusted EBITDA (non-GAAP)[1] Guidance Bridge[2,3]





Major impact in May guidance is driven by COVID-19 and FX

BAUSCH Health

1. See Slide 2 and Appendix for further non-GAAP information.
2. The guidance in this presentation is only effective as of the date given, May 7, 2020, and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance. Distribution or reference of this deck following May 7, 2020 does not constitute the Company re-affirming guidance.
3. See Slide 1 for further information on forward-looking statements.

Closing Remarks

Bausch + Lomb/International (~56% of Total Revenue[1])

Salix (~23% of Total Revenue[1])

Xifaxan® rifaximin 550 mg tablets

Trulance™ (plecanatide)

RELISTOR® methylnaltrexone bromide

Leading Durable Brands

Ortho Dermatologics (~7% of Total Revenue[1])

thermage® FLX

JUBLIA® (efinaconazole) Topical Solution 10%

Diversified Products (~14% of Total Revenue[1])

Aplenzin® bupropion HBr 174 mg 348 mg 522 mg extended-release tablets

Wellbutrin XL® bupropion HCl 150 mg, 300 mg EXTENDED-RELEASE TABLETS

1. For the Twelve Months Ended December 31, 2019.

Clinical Milestones to Watch[1]

SiHy Approval and Launch: Coming 2H20 in U.S.

- Received U.S. 510(k) filing acceptance
- Launching into daily disposables market which is the largest growing segment of contact lens wearers in the U.S.

New rifaximin soluble solid dispersion (SSD) for immediate release (IR)

- Positive topline results from a Phase 2 study
- 40 mg BID rifaximin SSD IR in combination with standard of care therapy treatment arm was statistically significantly superior to the placebo plus standard of care therapy treatment arm with median time to resolution being 21.1 hours versus 62.7 hours, respectively
- Will help inform further research on potential new indications for rifaximin using this new formulation. The first application will be in sickle cell anemia, with clinical trials expected to commence late 2020 or early 2021

Additional Rifaximin Studies

- Entered into a collaboration with Cedars Sinai Medical Center to evaluate a new formulation of rifaximin for the treatment of IBS
- Post-Operative Crohn's: Expected to initiate a Phase 2/3 study using a novel rifaximin extended release formulation in 2Q21[7]
- SIBO program: Novel, unique formulation targeting the small bowel to address Small Intestinal Bacterial Overgrowth
- Reduction in Encephalopathic Decompensation in Cirrhosis program: Novel, unique formulation targeting 'upstream' treatment in cirrhosis patients to prevent complications such as HE[4], SBP[5], bleeding and CKD[6]

Amiselimod S1P[2] Modulator[3]

- Completed the thorough QT study which evaluated the cardiac safety profile
- Topline results were positive; The primary endpoint demonstrated amiselimod has no effect on QT interval prolongation
  - QT interval prolongation has been associated with other molecules in this class
  - In addition, no other significant secondary safety signals were identified in this rigorous, well controlled clinical study
- Expect to initiate Phase 2 study in 2H20

BAUSCH Health

1. See Slide 1 for further information on forward-looking statements.
2. Sphingosine 1-phosphate.
3. Exclusive licensing agreement with Mitsubishi Tanabe Pharma.
4. Hepatic Encephalopathy.
5. Spontaneous bacterial peritonitis.
6. Chronic kidney disease.
7. Study being run by partner, Alfasigma S.p.A.

Global, Diversified Business Model Built for Growth

Diverse Product Portfolio

more than
15 **products launched**
in 2019

~1,400
Products across
4 Segments
serving a broad array of therapeutic areas

Diverse Mix of
Rx, OTC and Device revenue

Global Footprint

Every day, around the world
150M+ People
use a Bausch Health product

Products sold in
~100
Countries

Expect revenue to grow at a 3%-5% CAGR[2]

Deliver on 3-year CAGRs[2]
(constant currency and from the mid-point of 2019 guidance[3])

Expect adj. EBITDA (non-GAAP)[1] to grow at a 4%-7% CAGR[2]

BAUSCH Health

1. See Slide 2 and Appendix for further non-GAAP information.
2. Compound Annual Growth Rate.
3. Based on Guidance issued in Feb. 2019.

Appendix

Pipeline and Portfolio Expansion: Late Stage Development[1]

- **Our R&D programs continue to progress. Clinical trials that had started prior to governmental shutdowns remain enrolled and existing patients are progressing; however, new patient enrollments in clinical trials have been temporarily paused due to most investigational sites not being able to accept new patients due to the COVID-19 pandemic.**
- **We plan to resume new patient enrollment in clinical trials once COVID-19 related restrictions have been lifted. Some geographies may be able to open investigational sites before others, and we will allow them to resume participation as soon as possible.**

BAUSCH + LOMB

- SiHy Daily – **Launched in Japan; U.S. launch expected 2H20**
- LUMIFY® Line Extensions – **Further clinical studies planned for late 2020/early 2021**
- Extended Depth of Focus (EDOF) Intraocular Lens – **Anticipate approval in Europe in 2H21 due to COVID-19 delays**
- New Ophthalmic Viscosurgical Device – **Filing of premarket approval application for dispersive OVD completed April 2020**
- enVista® Trifocal (Intraocular Lens) – **Initiated IDE[2] study in May 2018; Phase 2 initiated in Oct 2019**
- Preloaded intraocular lens injector platform for enVista interocular lens – **Received approvals from the EU and Canada and received FDA clearance of the injector; Anticipate launching this platform in 2H20**
- Custom soft contact lens (Ultra buttons) – **Expected launch in 4Q21 if approved by the FDA**
- XIPERE™[3] (investigational treatment for macular edema associated with uveitis) – **Expected resubmission of NDA to FDA in 4Q20**
- EM-100 (OTC preservative-free eye drop for the treatment of ocular itching associated with allergic conjunctivitis) – **Resubmitted to FDA; Response expected in 2H20**
- NOV03[4] (dry eye disease associated with meibomian gland dysfunction) – **Expect to initiate additional Phase 3 study in 2H20**

Salix Pharmaceuticals

- Amiselimod S1P[5] Modulator[6] – **Completed the thorough QT study which evaluated the cardiac safety profile; topline results were positive and expect to initiate Phase 2 study in 2H20**
- Rifaximin (OHE[7]) – **Topline data from our Phase 2 study for the treatment of OHE with a new formulation of rifaximin showed a treatment benefit; The topline results of this study will help inform further research on potential new indications for rifaximin using this new formulation. The first application will be in sickle cell anemia, with clinical trials expected to commence late 2020 or early 2021.**
- Rifaximin (SIBO[8]) – **Phase 2 trial preparations underway**
- Rifaximin (Crohn's) – **Phase 2/3 study expected to start in 2Q21[9]**
- Probiotic – **Clinical trial completed; Launch expected in 2H20**

Ortho Dermatologics

- IDP-120 (Acne) – **Phase 3 enrollment completed with results expected in 2H20**
- ARAZLO™ (formerly IDP-123 - Acne) – **Launch expected in 1H20**
- IDP-124 (Atopic Dermatitis) – **Phase 3 enrollment completed with results expected in 2H20**
- IDP-126 (Acne Combination) – **Phase 3 trial ongoing**
- IDP-131 (Psoriasis) – **Topical proof of concept study completed. It did not meet expectations. Will not be developed for psoriasis.**

1. See slide 1 for further information on forward-looking statements.
2. Investigational device exemption.
3. Exclusive licensing agreement with Clearside Biomedical, Inc.
4. Exclusive licensing agreement with Novaliq GmbH.
5. Sphingosine 1-phosphate.
6. Exclusive licensing agreement with Mitsubishi Tanabe Pharma.
7. Overt hepatic encephalopathy.
8. Small intestinal bacterial overgrowth.
9. Study being run by partner, Alfasigma S.p.A.

Key Product LOE Q1 2020 Impact

Business Unit	Product Line with Actual or Anticipated LOE Date[1]	LOE Rev/Profit Q1 2019 Actual		LOE Rev/Profit Q1 2020 Actual		Change Q1 2019 vs. Q1 2020	
		Revenue	Profit	Revenue	Profit	Revenue	Profit
Ophtho Rx	• Lotemax Suspension® 2Q19 • Lotemax Gel® 2021 (not date certain)	$27M	$27M	$7M	$7M	($20M)	($20M)
Int'l	• Glumetza® 1Q17 • Tiazac® XC 1H20 (not date certain) • Lodalis 1H20 (not date certain)	$9M	$7M	$13M	$10M	$4M	$3M
BAUSCH + LOMB/INTERNATIONAL		**$36M**	**$34M**	**$20M**	**$17M**	**($16M)**	**($17M)**
SALIX	• Zegerid® add't US Gx 2017 • Uceris® 3Q18 • Apriso® 4Q19 • Moviprep® 1H20 (not date certain)	**$55M**	**$43M**	**$15M**	**$11M**	**($40M)**	**($32M)**
ORTHO DERMATOLOGICS	• Solodyn® 1Q18/19 • Acanya® 3Q18 • Elidel® 4Q18 • Zovirax® (Cream) 1Q19	**$20M**	**$19M**	**$5M**	**$5M**	**($15M)**	**($14M)**
DIVERSIFIED PRODUCTS	• Xenazine® Gx and brand competition 2Q17 • Isuprel® 3Q17 • Syprine® 1Q18 • Mephyton® 2Q18 • Cuprimine® 2Q19 • Migranal Franchise 2Q20	**$64M**	**$62M**	**$33M**	**$30M**	**($31M)**	**($32M)**
OVERALL COMPANY		**$175M**	**$158M**	**$73M**	**$63M**	**($102M)**	**($95M)**

BAUSCH Health

1. *Anticipated date of loss of exclusivity is based on the Company's current best estimate and actual date of LOE, as the case may be, may occur earlier or later. Changes from prior forecast are noted in red.*

Key Product LOE 2020 Impact

Business Unit	Product Line with Actual or Anticipated LOE Date[1]	LOE Rev/Profit Prior Forecast		LOE Rev/Profit Latest Forecast		Change Prior Forecast vs Latest Forecast	
		Revenue	Profit	Revenue	Profit	Revenue	Profit
Ophtho Rx	• Lotemax Suspension® 2Q19 • Lotemax Gel® 2021 (not date certain)	$27M	$26M	$22M	$21M	($5M)	($5M)
Int'l	• Glumetza® 1Q17 • Tiazac® XC 1H20 (not date certain) • Lodalis 1H20 (not date certain)	$37M	$30M	$41M	$33M	$4M	$3M
BAUSCH + LOMB/INTERNATIONAL		**$64M**	**$56M**	**$63M**	**$54M**	**($1M)**	**($2M)**
SALIX	• Zegerid® add't US Gx 2017 • Uceris® 3Q18 • Apriso® 4Q19 • Moviprep® 1H20 (not date certain)	**$67M**	**$52M**	**$58M**	**$44M**	**($9M)**	**($8M)**
ORTHO DERMATOLOGICS	• Solodyn® 1Q18/19 • Acanya® 3Q18 • Elidel® 4Q18 • Zovirax® (Cream) 1Q19	**$16M**	**$15M**	**$19M**	**$18M**	**$3M**	**$3M**
DIVERSIFIED PRODUCTS	• Xenazine® Gx and brand competition 2Q17 • Isuprel® 3Q17 • Syprine® 1Q18 • Mephyton® 2Q18 • Cuprimine® 2Q19 • Migranal Franchise 2Q20	**$140M**	**$128M**	**$116M**	**$104M**	**($24M)**	**($24M)**
OVERALL COMPANY		**$287M**	**$251M**	**$256M**	**$220M**	**($31M)**	**($31M)**

BAUSCH Health

1. *Anticipated date of loss of exclusivity is based on the Company's current best estimate and actual date of LOE, as the case may be, may occur earlier or later. Changes from prior forecast are noted in red.*

Key Product LOE 2020 Impact vs. 2019

Business Unit	Product Line with Actual or Anticipated LOE Date[1]	LOE Rev/Profit 2019 Actual		LOE Rev/Profit 2020 Forecast		Change 2019 vs 2020 Forecast	
		Revenue	Profit	Revenue	Profit	Revenue	Profit
Ophtho Rx	• Lotemax Suspension® 2Q19 • Lotemax Gel® 2021 (not date certain)	$87M	$85M	$22M	$21M	($65M)	($64M)
Int'l	• Glumetza® 1Q17 • Tiazac® XC 1H20 (not date certain) • Lodalis 1H20 (not date certain)	$45M	$37M	$41M	$33M	($4M)	($4M)
BAUSCH + LOMB/INTERNATIONAL		**$132M**	**$122M**	**$63M**	**$54M**	**($69M)**	**($68M)**
SALIX	• Zegerid® add't US Gx 2017 • Uceris® 3Q18 • Apriso® 4Q19 • Moviprep® 1H20 (not date certain)	**$196M**	**$151M**	**$58M**	**$44M**	**($138M)**	**($107M)**
ORTHO DERMATOLOGICS	• Solodyn® 1Q18/19 • Acanya® 3Q18 • Elidel® 4Q18 • Zovirax® (Cream) 1Q19	**$46M**	**$41M**	**$19M**	**$18M**	**($27M)**	**($23M)**
DIVERSIFIED PRODUCTS	• Xenazine® Gx and brand competition 2Q17 • Isuprel® 3Q17 • Syprine® 1Q18 • Mephyton® 2Q18 • Cuprimine® 2Q19 • Migranal Franchise 2Q20	**$194M**	**$175M**	**$116M**	**$104M**	**($78M)**	**($71M)**
OVERALL COMPANY		**$568M**	**$489M**	**$256M**	**$220M**	**($312M)**	**($269M)**

BAUSCH Health

1. *Anticipated date of loss of exclusivity is based on the Company's current best estimate and actual date of LOE, as the case may be, may occur earlier or later. Changes from prior forecast are noted in red.*

Selected U.S. Businesses Pipeline Inventory Trending (1Q20)

Months on Hand						
Business Units	**As of Dec 31, 2018**	**As of Mar 31, 2019**	**Change 1Q19**	**As of Dec 31, 2019**	**As of Mar 31, 2020**	**Change 1Q20**
Derm	1.26	1.33	0.07	0.88	1.27	0.39
Neuro	1.08	1.06	(0.02)	0.83	0.83	0.00
Ophtho	0.89	0.87	(0.02)	0.71	1.01	0.30
GI	0.99	1.01	0.02	0.79	0.82	0.03

1Q 20 Financial Results

Bausch + Lomb/International

	Three Months Ended		Favorable (Unfavorable)		
	3.31.20	*3.31.19*	*Reported*	*Constant Currency*[1,2]	*Organic Change*[1,3]
Global Vision Care Revenue	$193M	$203M	(5%)	(4%)	(3%)
Global Surgical Revenue	$153M	$167M	(8%)	(7%)	(6%)
Global Consumer Revenue	$353M	$324M	9%	11%	12%
Global Ophtho Rx Revenue	$132M	$161M	(18%)	(17%)	(16%)
International Rx Revenue	$283M	$263M	8%	8%	9%
Total Segment Revenue	**$1,114M**	**$1,118M**	**0%**	**1%**	**2%**
Gross Profit[4] (excluding amortization and impairments of intangible assets)	**$710M**	**$707M**	**0%**	**2%**	
Gross Margin	*63.7%*	*63.2%*	*50 bps*		
Selling, A&P	$315M	$317M	1%	(1%)	
G&A	$40M	$41M	2%	0%	
R&D	$30M	$30M	0%	(3%)	
Total Operating Expense	**$385M**	**$388M**	**1%**	**(1%)**	
EBITA (non-GAAP)[1]	**$325M**	**$319M**	**2%**	**4%**	
EBITA Margin (non-GAAP)[1]	29%	29%			
Revenue % of total	55%	55%			
EBITA % (non-GAAP)[1] **of total**	43%	40%			

+2%

Bausch + Lomb/International segment organic revenue growth[1,3] **vs. 1Q19, driven primarily by Global Consumer and International Rx**

BAUSCH Health

1. See Slide 2 and Appendix for further non-GAAP information.
2. See Appendix for further information on the use and calculation of constant currency.
3. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.
4. See the Appendix for details on amortization and impairments of intangible assets.

1Q 20 Financial Results

Salix

	Three Months Ended		Favorable (Unfavorable)		
	3.31.20	*3.31.19*	*Reported*	*Constant Currency*[1,2]	*Organic Change*[1,3]
Salix Revenue	$477M	$445M	7%	7%	4%
Total Segment Revenue	**$477M**	**$445M**	**7%**	**7%**	**4%**
Adj. Gross Profit (non-GAAP)[1,4,5] (excluding amortization and impairments of intangible assets)	**$424M**	**$381M**	**11%**	**11%**	
Adj. Gross Margin (non-GAAP)[1,5]	*88.9%*	*85.6%*	*330 bps*		
Selling, A&P	$78M	$73M	(7%)	(7%)	
G&A	$15M	$11M	(36%)	(36%)	
R&D	$12M	$8M	(50%)	(50%)	
Total Operating Expense	**$105M**	**$92M**	**(14%)**	**(14%)**	
Adj. EBITA (non-GAAP)[1,5]	**$319M**	**$289M**	**10%**	**10%**	
Adj. EBITA Margin (non-GAAP)[1,5]	*67%*	*65%*			
Revenue % of total	***24%***	***22%***			
EBITA % (non-GAAP)[1,5] **of total**	***42%***	***37%***			

+4%

Salix segment organic revenue growth[1,3] vs. 1Q19, driven primarily by XIFAXAN® which reported 23% revenue growth; in 1Q20, Salix had an LOE revenue drag of ~$40M, primarily due to APRISO®

1. See Slide 2 and Appendix for further non-GAAP information.
2. See Appendix for further information on the use and calculation of constant currency.
3. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.
4. See the Appendix for details on amortization and impairments of intangible assets.
5. 2020 numbers are on an as reported basis, no adjustments reflected in 2020.

1Q 20 Financial Results

Ortho Dermatologics

	Three Months Ended		Favorable (Unfavorable)		
	3.31.20	*3.31.19*	*Reported*	*Constant Currency[1,2]*	*Organic Change[1,3]*
Ortho Dermatologics Revenue	$82M	$100M	(18%)	(18%)	(18%)
Global Solta Revenue	$51M	$38M	34%	37%	37%
Total Segment Revenue	**$133M**	**$138M**	**(4%)**	**(3%)**	**(3%)**
Gross Profit[4] (excluding amortization and impairments of intangible assets)	**$113M**	**$120M**	**(6%)**	**(6%)**	
Gross Margin	*85.0%*	*87.0%*	*(200 bps)*		
Selling, A&P	$47M	$46M	(2%)	(4%)	
G&A	$9M	$6M	(50%)	(33%)	
R&D	$9M	$11M	18%	18%	
Total Operating Expense	**$65M**	**$63M**	**(3%)**	**(3%)**	
EBITA (non-GAAP)[1]	**$48M**	**$57M**	**(16%)**	**(14%)**	
EBITA Margin (non-GAAP)[1]	*36%*	*41%*			
Revenue % of total	***7%***	***7%***			
EBITA % (non-GAAP)[1] of total	***6%***	***7%***			

+37%

Global Solta organic revenue growth[1,3] vs. 1Q19, driven by continued strong demand of Thermage® FLX

In 1Q20, Ortho Dermatologics business unit had an LOE revenue drag of ~$15M; LOEs included SOLODYN®, ZOVIRAX®, ELIDEL® and ACANYA®

1. See Slide 2 and Appendix for further non-GAAP information.
2. See Appendix for further information on the use and calculation of constant currency.
3. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.
4. See the Appendix for details on amortization and impairments of intangible assets.

BAUSCH Health

1Q 20 Financial Results

Diversified Products

	Three Months Ended		Favorable (Unfavorable)		
	3.31.20	*3.31.19*	*Reported*	*Constant Currency*[1,2]	*Organic Change*[1,3]
Neuro & Other Revenue	$162M	$186M	(13%)	(13%)	(13%)
Generics Revenue	$105M	$104M	1%	1%	1%
Dentistry Revenue	$21M	$25M	(16%)	(16%)	(16%)
Total Segment Revenue	**$288M**	**$315M**	**(9%)**	**(9%)**	**(9%)**
Gross Profit[4] (excluding amortization and impairments of intangible assets)	**$246M**	**$272M**	**(10%)**	**(10%)**	
Gross Margin	*85.4%*	*86.3%*	*(90 bps)*		
Selling, A&P	$29M	$26M	(12%)	(12%)	
G&A	$13M	$7M	(86%)	(86%)	
R&D	$2M	$3M	33%	33%	
Total Operating Expense	**$44M**	**$36M**	**(22%)**	**(22%)**	
EBITA (non-GAAP)[1]	**$202M**	**$236M**	**(14%)**	**(14%)**	
EBITA Margin (non-GAAP)[1]	70%	75%			
Revenue % of total	**14%**	**16%**			
EBITA % (non-GAAP)[1] of total	**27%**	**30%**			

+14%

WELLBUTRIN®[5]/APLENZIN® combined reported revenue growth vs. 1Q19; driven by APLENZIN®, which saw 63% reported revenue growth vs. 1Q19

BAUSCH Health

1. See Slide 2 and Appendix for further non-GAAP information.
2. See Appendix for further information on the use and calculation of constant currency.
3. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.
4. See the Appendix for details on amortization and impairments of intangible assets
5. U.S. sales only.

Other Financial Information (Quarter-to-Date)

	Three Months Ended		Favorable (Unfavorable)	
	March 31, 2020	March 31, 2019	Reported	Constant Currency[1,2]
Cash Interest Expense	$381M	$389M	2%	2%
Net Interest Expense	$389M	$402M	3%	3%
Non-cash adjustments				
Depreciation	$45M	$43M	(5%)	(5%)
Non-cash share-based Comp	$27M	$24M	(13%)	(13%)
Additional cash items				
Contingent Consideration	$17M	$9M		
Milestones/License Agreements and Other Intangibles	$29M	$0M		
Restructuring and Other	$27M	$24M		
Capital Expenditures	$72M	$47M		
Adj. Tax Rate[1]	10.4%	6.3%		

BAUSCH Health

1. See Slide 2 and this Appendix for further non-GAAP information.
2. See this Appendix for further information on the use and calculation of constant currency.

1Q 20

Top 10 Products – Total BAUSCH Health[1]

Top 10 products/franchises revenues and trailing five quarters

Rank	Product/Franchises	1Q20	4Q19	3Q19	2Q19	1Q19
1	XIFAXAN®	**$375M**	$396M	$394M	$356M	$306M
2	Ocuvite® + PreserVision®	**$72M**	$86M	$79M	$84M	$64M
3	WELLBUTRIN®	**$62M**	$64M	$69M	$70M	$66M
4	SofLens®	**$58M**	$70M	$72M	$72M	$70M
5	Biotrue® ONEday	**$47M**	$40M	$50M	$46M	$42M
6	renu®	**$42M**	$62M	$54M	$53M	$48M
7	Thermage®	**$41M**	$48M	$35M	$33M	$27M
8	Bausch + Lomb ULTRA®[2]	**$40M**	$35M	$35M	$31M	$29M
9	Biotrue® Multi-Purpose Solution	**$34M**	$37M	$33M	$36M	$29M
10	RELISTOR®	**$32M**	$27M	$33M	$24M	$28M

BAUSCH Health

1. Global sales.
2. As of Q3 2019, we removed certain daily disposable products from the Ultra family. The history has also been adjusted to provide an accurate historical comparison.

1Q 20

Top 10 Products – B+L/International

Top 10 products/franchises revenues and trailing five quarters

Rank	Product/Franchises	1Q20	4Q19	3Q19	2Q19	1Q19
1	Ocuvite® + PreserVision®	**$72M**	$86M	$79M	$84M	$64M
2	SofLens®	**$58M**	$70M	$72M	$72M	$70M
3	Biotrue® ONEday	**$47M**	$40M	$50M	$46M	$42M
4	renu®	**$42M**	$62M	$54M	$53M	$48M
5	Bausch + Lomb ULTRA®[1]	**$40M**	$35M	$35M	$31M	$29M
6	Biotrue® Multi-Purpose Solution	**$34M**	$37M	$33M	$36M	$29M
7	PureVision®	**$24M**	$26M	$28M	$28M	$27M
8	Anterior Disposables	**$23M**	$27M	$23M	$25M	$25M
9	Boston Solutions	**$23M**	$20M	$18M	$19M	$18M
10	ARTELAC®	**$22M**	$24M	$24M	$24M	$22M

BAUSCH Health

1. As of Q3 2019, we removed certain daily disposable products from the Ultra family. The history has also been adjusted to provide an accurate historical comparison.

1Q 20

Top 10 Products – Salix[1]

Top 10 products/franchises revenues and trailing five quarters

Rank	Product/Franchises	1Q20	4Q19	3Q19	2Q19	1Q19
1	XIFAXAN®	**$375M**	$396M	$394M	$356M	$306M
2	RELISTOR®	**$31M**	$27M	$33M	$24M	$26M
3	GLUMETZA®	**$21M**	$24M	$41M	$42M	$38M
4	TRULANCE®	**$19M**	$18M	$14M	$17M	$6M
5	APRISO®	**$7M**	$25M	$40M	$44M	$36M
6	UCERIS®	**$6M**	$7M	$7M	$7M	$11M
7	ZEGERID®	**$4M**	$4M	$3M	$4M	$5M
8	CYCLOSET®	**$3M**	$3M	$3M	$4M	$3M
9	PLENVU®	**$3M**	$4M	$3M	$3M	$2M
10	AZASAN®	**$2M**	$2M	$4M	$2M	$2M

1. U.S. sales only

1Q 20

Top 10 Products – Ortho Dermatologics

Top 10 products/franchises revenues and trailing five quarters

Rank	Product/Franchises	1Q20	4Q19	3Q19	2Q19	1Q19
1	THERMAGE®	**$41M**	$48M	$35M	$33M	$27M
2	JUBLIA®	**$19M**	$19M	$22M	$15M	$11M
3	RETIN-A®1	**$11M**	$6M	$4M	$5M	$9M
4	RETIN-A MICRO®.06 & .08	**$8M**	$7M	$9M	$9M	$12M
5	TARGRETIN®	**$7M**	$15M	$11M	$9M	$9M
6	SILIQ®	**$7M**	$7M	$8M	$8M	$5M
7	ONEXTON®	**$6M**	$5M	$8M	$6M	$12M
8	ELIDEL®	**$5M**	$6M	$8M	$7M	$8M
9	CLINDAGEL®	**$5M**	$5M	$5M	$7M	$3M
10	Vaser®	**$4M**	$5M	$5M	$4M	$4M

BAUSCH Health

1. *Excludes RETIN-A Micro® 0.06% and 0.08%.*

1Q 20

Top 10 Products – Diversified Products[1]

Top 10 products/franchises revenues and trailing five quarters

Rank	Product/Franchises	1Q20	4Q19	3Q19	2Q19	1Q19
1	WELLBUTRIN®	$58M	$61M	$64M	$61M	$58M
2	APLENZIN®	$26M	$24M	$22M	$21M	$16M
3	ARESTIN®	$19M	$23M	$22M	$21M	$21M
4	DIASTAT®	$11M	$10M	$12M	$7M	$6M
5	MIGRANAL®	$10M	$15M	$15M	$13M	$12M
6	NEO/POLY/HC OTIC	$9M	$5M	$5M	$7M	$5M
7	UCERIS® AG	$9M	$17M	$9M	$15M	$5M
8	APRISO® AG	$8M	$5M	$0M	$0M	$0M
9	ATIVAN®	$8M	$9M	$9M	$10M	$15M
10	TOBRAMYCIN/ DEXAMETHASONE	$8M	$8M	$7M	$9M	$7M

BAUSCH Health

1. U.S. only sales.

Non-GAAP Adjustments EPS Impact ($M)

	Three Months Ended March 31,			
	2020		2019	
	Income (Expense)	Earnings per Share Impact	Income (Expense)	Earnings per Share Impact
Net loss attributable to Bausch Health Companies Inc.	$ (152)	$ (0.43)	$ (52)	$ (0.15)
Non-GAAP adjustments:				
Amortization of intangible assets	436	1.22	489	1.37
Asset impairments	14	0.04	3	0.01
Restructuring and integration costs	4	0.01	20	0.06
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	13	0.04	(12)	(0.03)
Loss on extinguishment of debt	24	0.07	7	0.02
Litigation and other matters	23	0.06	2	0.01
Acquired in-process research and development costs	1	-	1	-
IT infrastructure investment	7	0.02	4	0.01
Legal and other professional fees	9	0.03	8	0.02
Net gain on sale of assets	(1)	-	(10)	(0.03)
Other	-	-	(4)	(0.01)
Tax effect of non-GAAP adjustments	(62)	(0.17)	(98)	(0.28)
EPS difference between basic and diluted shares		(0.01)		0.01
Adjusted net income attributable to Bausch Health Companies Inc. (non-GAAP)[1]	**$ 316**		**$ 358**	

BAUSCH Health

1. *See Slide 2 and this Appendix for further non-GAAP information.*

Bausch + Lomb/Int'l Segment Trailing Five Quarters[1]

Bausch + Lomb/International	1Q20	4Q19	3Q19	2Q19	1Q19
Global Vision Care Revenue	$193M	$210M	$219M	$216M	$203M
Global Surgical Revenue	$153M	$193M	$161M	$177M	$167M
Global Consumer Revenue	$353M	$390M	$370M	$371M	$324M
Global Ophtho Rx Revenue	$132M	$155M	$150M	$172M	$161M
International Rx Revenue	$283M	$290M	$275M	$272M	$263M
Segment Revenue	**$1,114M**	**$1,238M**	**$1,175M**	**$1,208M**	**$1,118M**
Segment Gross Profit[3] (excluding amortization and impairments of intangible assets)	$710M	$741M	$730M	$748M	$707M
Segment Gross Margin	63.7%	59.9%	62.1%	61.9%	63.2%
Segment R&D	$30M	$29M	$36M	$31M	$30M
Segment SG&A	$355M	$369M	$361M	$380M	$358M
Segment Profit/EBITA (non-GAAP)[2]	$325M	$343M	$333M	$337M	$319M

BAUSCH Health

1. Products with sales outside the United States impacted by F/X changes.
2. See Slide 2 and this Appendix for further non-GAAP information.
3. See this Appendix for details on amortization and impairments of intangible assets.

Salix Segment Trailing Five Quarters

Salix	1Q20[2]	4Q19[2]	3Q19[2]	2Q19[1]	1Q19[1]
Salix Revenue	$477M	$517M	$551M	$509M	$445M
Segment Revenue	**$477M**	**$517M**	**$551M**	**$509M**	**$445M**
Adj. Segment Gross Profit (non-GAAP)[1,2,3] (excluding amortization and impairments of intangible assets)	$424M	$458M	$489M	$439M	$381M
Adj. Segment Gross Margin (non-GAAP)[1,2]	88.9%	88.6%	88.7%	86.2%	85.6%
Segment R&D	$12M	$16M	$7M	$5M	$8M
Segment SG&A	$93M	$88M	$107M	$98M	$84M
Adj. Segment Profit/EBITA (non-GAAP)[1,2]	$319M	$354M	$375M	$336M	$289M

BAUSCH Health

1. *For 1Q and 2Q 2019, see Slide 2 and this Appendix for further non-GAAP information for adjusted segment gross profit (non-GAAP), adjusted segment gross margin (non-GAAP) and adjusted segment profit/EBITA (non-GAAP).*
2. *For 3Q and 4Q 2019 and 1Q20, amounts are on an as reported basis so no adjustments reflected for segment gross profit, segment gross margin and segment profit.*
3. *See this Appendix for details on amortization and impairments of intangible assets.*

Ortho Dermatologics Segment Trailing Five Quarters[1]

Ortho Dermatologics	1Q20	4Q19	3Q19	2Q19	1Q19
Ortho Dermatologics Revenue	$82M	$94M	$100M	$77M	$100M
Global Solta Revenue[1]	$51M	$64M	$47M	$45M	$38M
Segment Revenue	**$133M**	**$158M**	**$147M**	**$122M**	**$138M**
Segment Gross Profit[3] (excluding amortization and impairments of intangible assets)	$113M	$132M	$123M	$103M	$120M
Segment Gross Margin	85.0%	83.5%	83.7%	84.4%	87.0%
Segment R&D	$9M	$9M	$9M	$9M	$11M
Segment SG&A	$56M	$57M	$56M	$53M	$52M
Segment Profit/EBITA (non-GAAP)[2]	$48M	$66M	$58M	$41M	$57M

BAUSCH Health

1. Products with sales outside the United States impacted by F/X changes.
2. See Slide 2 and this Appendix for further non-GAAP information.
3. See this Appendix for details on amortization and impairments of intangible assets.

Diversified Products Segment Trailing Five Quarters

Diversified Products	1Q20	4Q19	3Q19	2Q19	1Q19
Neuro & Other Revenue	$162M	$168M	$186M	$175M	$186M
Generics Revenue	$105M	$117M	$126M	$112M	$104M
Dentistry Revenue	$21M	$26M	$24M	$26M	$25M
Segment Revenue	**$288M**	**$311M**	**$336M**	**$313M**	**$315M**
Segment Gross Profit[2] (excluding amortization and impairments of intangible assets)	$246M	$258M	$284M	$271M	$272M
Segment Gross Margin	85.4%	83.0%	84.5%	86.6%	86.3%
Segment R&D	$2M	$1M	$5M	$4M	$3M
Segment SG&A	$42M	$39M	$33M	$35M	$33M
Segment Profit/EBITA (non-GAAP)[1]	$202M	$218M	$246M	$232M	$236M

BAUSCH Health

1. See Slide 2 and this Appendix for further non-GAAP information.
2. See this Appendix for details on amortization and impairments of intangible assets.

Reconciliation of Reported Operating Income to Adjusted EBITA (non-GAAP)[1] ($M) (Quarter-to-Date)

	Q1 2020						
	Gross Profit[2]	Gross Margin[2]	Selling & Advertising	G&A and Other	R&D Expense	Operating Expense	Operating Income
Qtr 1 2020 GAAP	**$ 1,493**	**74.2%**	**$ 469**	**$ 164**	**$ 122**	**$ 755**	**$ 248**
Amortization of finite-lived intangibles		0.0%				-	436
Asset Impairments		0.0%				-	14
Restructuring and integration costs		0.0%				-	4
Acquisition-related costs and adjustments (excluding amortization of intangible assets)		0.0%				-	13
Litigation and other matters		0.0%				-	23
Acquired in-process research and development costs		0.0%				-	1
IT infrastructure investment		0.0%		(7)		(7)	7
Legal and other professional fees		0.0%		(9)		(9)	9
Net (gain)/loss on sale of assets		0.0%				-	(1)
Qtr 1 2020 Non-GAAP[1]	**$ 1,493**	**74.2%**	**$ 469**	**$ 148**	**$ 122**	**$ 739**	**$ 754**

	Q1 2019						
	Gross Profit[2]	Gross Margin[2]	Selling & Advertising	G&A and Other	R&D Expense	Operating Expense	Operating Income
Qtr 1 2019 GAAP	**$ 1,479**	**73.4%**	**$ 462**	**$ 125**	**$ 117**	**$ 704**	**$ 287**
Amortization of finite-lived intangibles		0.0%				-	489
Asset Impairments		0.0%				-	3
Restructuring and integration costs		0.0%				-	20
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	1	0.0%				-	(12)
Litigation and other matters		0.0%				-	2
Acquired in-process research and development costs		0.0%				-	1
IT infrastructure investment		0.0%		(4)		(4)	4
Legal and other professional fees		0.0%		(8)		(8)	8
Net loss (gain) on sale of assets		0.0%				-	(10)
Other non-GAAP charges		0.0%				-	(4)
Qtr 1 2019 Non-GAAP[1]	**$ 1,480**	**73.4%**	**$ 462**	**$ 113**	**$ 117**	**$ 692**	**$ 788**

BAUSCH Health

1. See Slide 2 and this Appendix for further non-GAAP information.
2. Excluding amortization impairments of intangible assets.

Reconciliation of Reported Salix Segment Profit to Adjusted EBITA (non-GAAP)[1] ($M)

	Q1 2019 Salix						
	Gross Profit[2]	Gross Margin[2]	Selling & Advertising	G&A and Other	R&D Expense	Operating Expense	Operating Income
Qtr 1 2019 GAAP	**$ 380**	**85.4%**	**$ 73**	**$ 11**	**$ 8**	**$ 92**	**$ 288**
Acquisition-related costs and adjustments excluding amortization of intangible assets	1	0.2%				-	1
Qtr 1 2019 Non-GAAP[1]	**$ 381**	**85.6%**	**$ 73**	**$ 11**	**$ 8**	**$ 92**	**$ 289**

	Q2 2019 Salix						
	Gross Profit[2]	Gross Margin[2]	Selling & Advertising	G&A and Other	R&D Expense	Operating Expense	Operating Income
Qtr 2 2019 GAAP	**$ 435**	**85.5%**	**$ 85**	**$ 13**	**$ 5**	**$ 103**	**$ 332**
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	4	0.7%				-	4
Qtr 2 2019 Non-GAAP[1]	**$ 439**	**86.2%**	**$ 85**	**$ 13**	**$ 5**	**$ 103**	**$ 336**

1. See Slide 2 and this Appendix for further non-GAAP information.
2. Excluding amortization and impairments of intangible assets.

BAUSCH Health

Amortization and Impairments of Intangible Assets ($M)

	Amortization of intangible assets									
	Q1 2020		Q4 2019		Q3 2019		Q2 2019		Q1 2019	
Bausch + Lomb / International	$	110	$	111	$	114	$	119	$	120
Salix		246		246		246		247		242
Ortho Dermatologics		41		48		73		73		73
Diversified Products		39		40		42		49		54
Total Company	**$**	**436**	**$**	**445**	**$**	**475**	**$**	**488**	**$**	**489**

	Asset impairments									
	Q1 2020		Q4 2019		Q3 2019		Q2 2019		Q1 2019	
Bausch + Lomb / International	$	-	$	13	$	9	$	-	$	-
Salix		-		-		-		-		-
Ortho Dermatologics		-		13		-		-		-
Diversified Products		14		-		24		13		3
Total Company	**$**	**14**	**$**	**26**	**$**	**33**	**$**	**13**	**$**	**3**

Reconciliation of Reported Net Loss to EBITDA (non-GAAP)[1] and Adjusted EBITDA (non-GAAP)[1] ($M)

	Three Months Ended March 31,			
	2020		2019	
Net loss attributable to Bausch Health Companies Inc.	**$**	**(152)**	**$**	**(52)**
Interest expense, net		389		402
Benefit from income taxes		(26)		(74)
Depreciation and amortization		481		532
EBITDA		**692**		**808**
Adjustments:				
Asset impairments		14		3
Restructuring and integration costs		4		20
Acquisition-related costs and adjustments (excluding amortization of intangible assets)		13		(12)
Loss on extinguishment of debt		24		7
Share-based compensation		27		24
Other adjustments:				
Litigation and other matters		23		2
IT infrastructure investment		7		4
Legal and other professional fees		9		8
Net gain on sale of assets		(1)		(10)
Acquired in-process research and development costs		1		1
Other		-		(4)
Adjusted EBITDA (non-GAAP)[1]	**$**	**813**	**$**	**851**

BAUSCH Health

1. See Slide 2 and this Appendix for further non-GAAP information.

Reconciliation of Reported Revenue to Organic Revenue[1,2] and Organic Revenue Growth[1,2] ($M) (Quarter-to-Date)

Calculation of Organic Revenue

	Three Months Ended March 31, 2020				Three Months Ended March 31, 2019			Change in Organic Revenue	
	Revenue as Reported	Changes in Exchange Rates (a)	Acquisition	Organic Revenue (Non-GAAP) (b)	Revenue as Reported	Divestitures and Discontinuations	Organic Revenue (Non-GAAP) (b)	Amount	Pct.
Bauch +Lomb / International									
Global Vision Care	193	2	-	195	203	(1)	202	(7)	-3%
Global Surgical	153	3	-	156	167	(1)	166	(10)	-6%
Global Consumer Products	353	8	-	361	324	(1)	323	38	12%
Global Ophtho Rx	132	2	-	134	161	(2)	159	(25)	-16%
International Rx	283	2	-	285	263	(2)	261	24	9%
Total Bausch + Lomb / International	1,114	17	-	1,131	1,118	(7)	1,111	20	2%
Salix									
Salix	477	-	(13)	464	445	-	445	19	4%
Ortho Dermatologics									
Ortho Dermatologics	82	-	-	82	100	-	100	(18)	-18%
Global Solta	51	1	-	52	38	-	38	14	37%
Total Ortho Dermatologics	133	1	-	134	138	-	138	(4)	-3%
Diversified Products									
Neurology & Other	162	-	-	162	186	-	186	(24)	-13%
Generics	105	-	-	105	104	-	104	1	1%
Dentistry	21	-	-	21	25	-	25	(4)	-16%
Total Diversified Products	288	-	-	288	315	-	315	(27)	-9%
Total revenues	**$ 2,012**	**$ 18**	**$ (13)**	**$ 2,017**	**$ 2,016**	**$ (7)**	**$ 2,009**	**$ 8**	**0%**

(a) The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.
(b) To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures. For additional information about the Company's use of such non-GAAP financial measures, refer to slide 2 and to this Appendix. Organic revenue (non-GAAP) for the current year is calculated as revenue as reported adjusted for the impact for changes in exchange rates (previously defined in this press release). Organic revenue (non-GAAP) for the prior year is calculated as revenue as reported less revenues attributable to divestitures and discontinuances during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period. Organic revenue is also adjusted for acquisitions.

BAUSCH Health

1. *See Slide 2 and this Appendix for further non-GAAP information*
2. *Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations..*

Reconciliation of U.S. Vision Care Reported Revenue to Organic Revenue[1,2] and Organic Revenue Growth[1,2] ($M)

Calculation of Organic Revenue

	Three Months Ended March 31, 2020				Three Months Ended March 31, 2019			Change in Organic Revenue	
	Revenue as Reported	Changes in Exchange Rates (a)	Acquisition	Organic Revenue (Non-GAAP) (b)	Revenue as Reported	Divestitures and Discontinuations	Organic Revenue (Non-GAAP) (b)	Amount	Pct.
US Vision Care	77	-	-	77	62	-	62	15	24%

(a) The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.
(b) To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures. For additional information about the Company's use of such non-GAAP financial measures, refer to slide 2 and to this Appendix. Organic revenue (non-GAAP) for the current year is calculated as revenue as reported adjusted for the impact for changes in exchange rates (previously defined in this press release). Organic revenue (non-GAAP) for the prior year is calculated as revenue as reported less revenues attributable to divestitures and discontinuances during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period. Organic revenue is also adjusted for acquisitions.

BAUSCH Health

1. *See Slide 2 and this Appendix for further non-GAAP information*
2. *Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations..*

Reconciliation of TTM[1] Adjusted EBITDA[2] ($M)

	Adjusted EBITDA (non-GAAP)[2]				
	TTM[1]	TTM[1]	TTM[1]	TTM[1]	TTM[1]
	Mar-20	Dec-19	Sep-19	Jun-19	Mar-19
Net loss attributable to Bausch Health Companies Inc.	**$ (1,888)**	**$ (1,788)**	**$ (616)**	**$ (917)**	**$ (1,619)**
Interest expense, net	1,587	1,600	1,624	1,637	1,663
(Benefit from) provision for income taxes	(6)	(54)	(185)	(116)	31
Depreciation and amortization	2,024	2,075	2,129	2,312	2,565
EBITDA	**$ 1,717**	**$ 1,833**	**$ 2,952**	**$ 2,916**	**$ 2,640**
Adjustments:					
Asset impairments	86	75	183	239	527
Goodwill impairments	-	-	109	109	109
Restructuring and integration costs	15	31	34	33	36
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	50	25	29	7	(23)
Loss on extinguishment of debt	59	42	84	84	99
Share-based compensation	105	102	99	95	90
Other adjustments:					
Litigation and other matters	1,422	1,401	15	(34)	(36)
IT infrastructure investment	27	24	15	9	4
Legal and other professional fees	36	35	39	51	55
Net (gain) loss on sale of assets	(22)	(31)	(30)	(3)	(4)
Acquired in-process research and development costs	41	41	9	8	1
Other	(3)	(7)	(7)	(9)	(5)
Adjusted EBITDA (non-GAAP)[2]	**$ 3,533**	**$ 3,571**	**$ 3,531**	**$ 3,505**	**$ 3,493**

BAUSCH Health

1. *Trailing twelve months.*
2. *See Slide 2 and this Appendix for further non-GAAP information..*

Non-GAAP Appendix

Description of Non-GAAP Financial Measures

Adjusted EBITDA (non-GAAP)

Adjusted EBITDA (non-GAAP) Adjustments

Adjusted EBITA

EBITA/EBITA Margin

Adjusted Gross Profit/Adjusted Gross Margin

Adjusted Selling, A&P/Adjusted SG&A

Total Adjusted Operating Expense

Adjusted Net Income (Loss) (non-GAAP)

Adjusted Net Income (non-GAAP) Adjustments

Organic Revenue / Organic Growth / Organic Change

Constant Currency

Description of Non-GAAP Financial Measures

To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures, as follows. These measures do not have any standardized meaning under GAAP and other companies may use similarly titled non-GAAP financial measures that are calculated differently from the way we calculate such measures. Accordingly, our non-GAAP financial measures may not be comparable to similar non-GAAP measures. We caution investors not to place undue reliance on such non-GAAP measures, but instead to consider them with the most directly comparable GAAP measures. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

Adjusted EBITDA (non-GAAP)

Adjusted EBITDA (non-GAAP) is GAAP net loss attributable to Bausch Health Companies Inc. (its most directly comparable GAAP financial measure) adjusted for interest expense, net, provision for (benefit from) income taxes, depreciation and amortization and certain other items, as further described below. Management believes that Adjusted EBITDA (non-GAAP), along with the GAAP measures used by management, most appropriately reflect how the Company measures the business internally and sets operational goals and incentives. In particular, the Company believes that Adjusted EBITDA (non-GAAP) focuses management on the Company's underlying operational results and business performance. As a result, the Company uses Adjusted EBITDA (non-GAAP) both to assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes Adjusted EBITDA (non-GAAP) is a useful measure to evaluate current performance. Adjusted EBITDA (non-GAAP) is intended to show our unleveraged, pre-tax operating results and therefore reflects our financial performance based on operational factors. In addition, cash bonuses for the Company's executive officers and other key employees are based, in part, on the achievement of certain Adjusted EBITDA (non-GAAP) targets.

Non-GAAP Appendix

Adjusted EBITDA (non-GAAP) is net loss attributable to the Company (its most directly comparable GAAP financial measure) adjusted for interest expense, net, provision for (benefit from) income taxes, depreciation and amortization and the following items:

Restructuring and integration costs: The Company has incurred restructuring costs as it implemented certain strategies, which involved, among other things, improvements to its infrastructure and operations, internal reorganizations and impacts from the divestiture of assets and businesses. In addition, in connection with its acquisition of certain assets of Synergy Pharmaceuticals Inc. ("Synergy"), the Company has incurred certain severance and integration costs. With regard to infrastructure and operational improvements which the Company has taken to improve efficiencies in the businesses and facilities, these tend to be costs intended to right size the business or organization that fluctuate significantly between periods in amount, size and timing, depending on the improvement project, reorganization or transaction. With regard to the severance and integration costs associated with the acquisition of certain assets of Synergy, these costs are specific to the acquisition itself and provided no benefit to the ongoing operations of the Company. As a result, the Company does not believe that such costs (and their impact) are truly representative of its underlying business. The Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.

Asset Impairments: The Company has excluded the impact of impairments of finite-lived and indefinite-lived intangible assets, as well as impairments of assets held for sale, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions and divestitures. The Company believes that the adjustments of these items correlate with the sustainability of the Company's operating performance. Although the Company excludes impairments, of intangible assets from measuring the performance of the Company and the business, the Company believes that it is important for investors to understand that intangible assets contribute to revenue generation.

Goodwill Impairments: The Company excludes the impact of goodwill impairments. When the Company has made acquisitions where the consideration paid was in excess of the fair value of the net assets acquired, the remaining purchase price is recorded as goodwill. For assets that we developed ourselves, no goodwill is recorded. Goodwill is not amortized but is tested for impairment. In January 2017, new accounting guidance was issued which simplifies the subsequent measurement of an impairment to goodwill. Under the new guidance, which the Company early adopted effective Jan. 1, 2018, the amount of goodwill impairment is measured as the excess of a reporting unit's carrying value over its fair value. Management excludes these charges in measuring the performance of the Company and the business.

Non-GAAP Appendix

Share-based Compensation: The Company has excluded recorded costs relating to share-based compensation. The Company believes that the exclusion of share-based compensation expense assists investors in the comparisons of operating results to peer companies. Share-based compensation expense can vary significantly based on the timing, size and nature of awards granted.

Acquisition-related costs and adjustments excluding amortization of intangible assets: The Company has excluded the impact of acquisition-related costs and fair value inventory step-up resulting from acquisitions as the amounts and frequency of such costs and adjustments are not consistent and are impacted by the timing and size of its acquisitions. In addition, the Company has excluded the impact of acquisition-related contingent consideration non-cash adjustments due to the inherent uncertainty and volatility associated with such amounts based on changes in assumptions with respect to fair value estimates, and the amount and frequency of such adjustments is not consistent and is significantly impacted by the timing and size of the Company's acquisitions, as well as the nature of the agreed-upon consideration.

Loss on extinguishment of debt: The Company has excluded loss on extinguishment of debt as this represents a cost of refinancing our existing debt and is not a reflection of our operations for the period. Further, the amount and frequency of such charges are not consistent and are significantly impacted by the timing and size of debt financing transactions and other factors in the debt market out of management's control.

Other Non-GAAP Charges: The Company has excluded certain other amounts, including legal and other professional fees incurred in connection with recent legal and governmental proceedings, investigations and information requests regarding certain of our legacy distribution, marketing, pricing, disclosure and accounting practices, litigation and other matters, and net gain on sales of assets. The Company has also excluded expenses associated with in-process research and development, as these amounts are inconsistent in amount and frequency and are significantly impacted by the timing, size and nature of acquisitions. Furthermore, as these amounts are associated with research and development acquired, the Company does not believe that they are a representation of the Company's research and development efforts during any given period. The Company has also excluded IT infrastructure investment, that are the result of other, non-comparable events to measure operating performance. These events arise outside of the ordinary course of continuing operations. Given the unique nature of the matters relating to these costs, the Company believes these items are not normal operating expenses. For example, legal settlements and judgments vary significantly, in their nature, size and frequency, and, due to this volatility, the Company believes the costs associated with legal settlements and judgments are not normal operating expenses. In addition, as opposed to more ordinary course matters, the Company considers that each of the recent proceedings, investigations and information requests, given their nature and frequency, are outside of the ordinary course and relate to unique circumstances. The Company believes that the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the Company from period to period and, therefore, provides useful supplemental information to investors. However, investors should understand that many of these costs could recur and that companies in our industry often face litigation.

Please also see the reconciliation tables in this appendix for further information as to how these non-GAAP measures are calculated for the periods presented.

Non-GAAP Appendix

Adjusted EBITA

Management uses this non-GAAP measure (the most directly comparable GAAP financial measure for which is Total GAAP Revenue less total operating expenses (GAAP)) to assess performance of its business units and operating and reportable segments, and the Company, in total, without the impact of foreign currency exchange fluctuations, fair value adjustments to inventory in connection with business combinations and integration related inventory charges and technology transfer costs. In addition, it excludes certain acquisition related contingent consideration, acquired in-process research and development, asset impairments, restructuring, integration and acquisition-related costs, amortization of finite-lived intangible assets, other non-GAAP charges for wind down operating costs, and legal and other professional fees relating to legal and governmental proceedings, investigations and information requests respecting certain of our distribution, marketing, pricing, disclosure and accounting practices. The Company believes the exclusion of such amounts provides supplemental information to management and the users of the financial statements to assist in the understanding of the financial results of the Company from period to period and, therefore, provides useful supplemental information to investors. Please also see the reconciliation tables in this appendix for further information as to how these non-GAAP measures are calculated for the periods presented.

EBITA/EBITA Margin

EBITA represents earnings before interest, taxes and amortizations.

Adjusted Gross Profit/Adjusted Gross Margin

Management uses these non-GAAP measures (the most directly comparable GAAP financial measures for which are gross profit and gross margin) to assess performance of its business units and operating and reportable segments, and the Company in total, without the impact of foreign currency exchange fluctuations, and fair value adjustments to inventory in connection with business combinations. Such measures are useful to investors as it provides a supplemental period-to-period comparison. Please also see the reconciliation tables in this appendix for further information as to how these non-GAAP measures are calculated for the periods presented.

Adjusted Selling, A&P/Adjusted G&A/Adjusted SG&A

Management uses these non-GAAP measures (the most directly comparable GAAP financial measure for which is selling, general and administrative) as a supplemental measure for period-to-period comparison. Adjusted Selling, General and Administrative excludes, as applicable, certain costs primarily related to legal and other professional fees relating to legal and governmental proceedings, investigations and information requests respecting certain of our distribution, marketing, pricing, disclosure and accounting practices. See the discussion under “Other Non-GAAP charges” above. Please also see the reconciliation tables in this appendix for further information as to how this non-GAAP measure is calculated for the periods presented.

Total Adjusted Operating Expense

Management uses this non-GAAP measure (the most directly comparable GAAP financial measure for which is total operating expenses (GAAP)) as a supplemental measure for period-to-period comparison. This non-GAAP measure allows investors to supplement the evaluation of operational efficiencies of the underlying business without the variability of items that the Company believes are not normal course of business. Please see the reconciliation tables in this appendix for further information as to how this non-GAAP measure is calculated for the period presented

Non-GAAP Appendix

Adjusted Net Income (Loss) (non-GAAP)

Historically, management has used Adjusted net income (loss) (non-GAAP) (the most directly comparable GAAP financial measure for which is GAAP Net loss) for strategic decision making, forecasting future results and evaluating current performance. This non-GAAP measure excludes the impact of certain items (as described below) that may obscure trends in the Company's underlying performance. By disclosing this non-GAAP measure, it is management's intention to provide investors with a meaningful, supplemental comparison of the Company's operating results and trends for the periods presented. It is management's belief that this measure is also useful to investors as such measure allowed investors to evaluate the Company's performance using the same tools that management uses to evaluate past performance and prospects for future performance. Accordingly, it is the Company's belief that adjusted net income (non-GAAP) is useful to investors in their assessment of the Company's operating performance and the valuation of the Company. It is also noted that, in recent periods, our GAAP net income (loss) was significantly lower than our adjusted net income (non-GAAP). Commencing in 2017, management of the Company identified and began using certain new primary financial performance measures to assess the Company's financial performance. However, management still believes that Adjusted net income (non-GAAP) may be useful to investors in their assessment of the Company and its performance.

Adjusted Net Income (non-GAAP) Adjustments

Adjusted net income (non-GAAP) is net loss attributable to Bausch Health Companies Inc. (its most directly comparable GAAP financial measure) adjusted for restructuring and integration costs, acquired in-process research and development costs, loss on extinguishment of debt, asset impairments, acquisition-related adjustments, excluding amortization, and other non-GAAP charges), as these adjustments are described above, and amortization of intangible assets as described below:

Amortization of intangible assets: The Company has excluded the impact of amortization of intangible assets, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions. The Company believes that the adjustments of these items correlate with the sustainability of the Company's operating performance. Although the Company excludes amortization of intangible assets from its non-GAAP expenses, the Company believes that it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in the amortization of additional intangible assets.

Please see the reconciliation tables in this appendix for further information as to how this non-GAAP measure is calculated for the periods presented.

Non-GAAP Appendix

Organic Revenue, Organic Growth and Organic Change

Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of recent acquisitions, divestitures and discontinuations (if applicable). Organic growth/change is change in GAAP Revenue (its most directly comparable GAAP financial measure) adjusted for certain items, as further described below, of businesses that have been owned for one or more years. Organic revenue is impacted by changes in product volumes and price. The price component is made up of two key drivers: (i) changes in product gross selling price and (ii) changes in sales deductions. The Company uses organic revenue and organic growth/change to assess performance of its business units and operating and reportable segments, and the Company in total, without the impact of foreign currency exchange fluctuations and recent acquisitions, divestitures and product discontinuations. The Company believes that such measures are useful to investors as they provide a supplemental period-to-period comparison.

Organic growth/organic change reflects adjustments for: (i) the impact of period-over-period changes in foreign currency exchange rates on revenues and (ii) the revenues associated with acquisitions, divestitures and discontinuations of businesses divested and/ or discontinued. These adjustments are determined as follows:

- *Foreign currency exchange rates:* Although changes in foreign currency exchange rates are part of our business, they are not within management's control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the business. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.
- *Acquisitions, divestitures and discontinuations:* In order to present period-over-period organic revenues (non-GAAP) on a comparable basis, revenues associated with acquisitions, divestitures and discontinuations are adjusted to include only revenues from those businesses and assets owned during both periods. Accordingly, organic revenue (non-GAAP) growth/change excludes from the current period, revenues attributable to each acquisition for twelve months subsequent to the day of acquisition, as there are no revenues from those businesses and assets included in the comparable prior period. Organic revenue (non-GAAP) growth/change excludes from the prior period, all revenues attributable to each divestiture and discontinuance during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period.

Please also see the reconciliation in this Appendix for further information as to how this non-GAAP measure is calculated for the periods presented.

Constant Currency

Changes in the relative values of non-U.S. currencies to the U.S. dollar may affect the Company's financial results and financial position. To assist investors in evaluating the Company's performance, we have adjusted for foreign currency effects.

Constant currency impact is determined by comparing 2020 reported amounts adjusted to exclude currency impact, calculated using 2019 monthly average exchange rates, to the actual 2019 reported amounts.